Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYLD antisense RNA 2 (CYLD-AS2) is a long non-coding RNA transcribed on the antisense strand to the CYLD locus. It does not encode a protein and is affiliated with the lncRNA gene class. Diseases associated with CYLD-AS2 include Brooke-Spiegler syndrome and familial cylindromatosis, both of which are linked to mutation or dysregulation of the neighboring CYLD gene, a tumor suppressor deubiquitinase. The functional roles of CYLD-AS2 itself remain unclear but may involve regulation of CYLD gene expression through antisense RNA mechanisms or chromatin structure. There are currently no drugs or direct interventions that target CYLD-AS2, and it is not considered a classical therapeutic target such as a receptor or enzyme[5].
Not applicable; CYLD-AS2 is not a direct drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CYLD antisense RNA 2 (CYLD-AS2).